Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2 results

Results by year

Filters applied: . Clear all
Page 1
Melatonin and Melatonin Agonists as Adjunctive Treatments in Bipolar Disorders.
Geoffroy PA, Etain B, Franchi JA, Bellivier F, Ritter P. Geoffroy PA, et al. Curr Pharm Des. 2015;21(23):3352-8. doi: 10.2174/1381612821666150619093448. Curr Pharm Des. 2015. PMID: 26088111 Review.
In order to evaluate the efficacy of melatonin among patients with BD, this comprehensive review emphasizes the abnormal melatonin function in BD, the rationale of melatonin action in BD, the available data about the exogenous administration of melatonin, and melatonin agonists ( …
In order to evaluate the efficacy of melatonin among patients with BD, this comprehensive review emphasizes the abnormal melatonin function …
New and emerging pharmacotherapeutic approaches for insomnia.
Neubauer DN. Neubauer DN. Int Rev Psychiatry. 2014 Apr;26(2):214-24. doi: 10.3109/09540261.2014.888990. Int Rev Psychiatry. 2014. PMID: 24892896 Review.
The FDA is reviewing new applications for innovative sleep-promoting medications currently, including suvorexant and tasimelteon. Presently the FDA-approved insomnia treatment medications include benzodiazepine receptor agonists available in immediate-release, extended-rel …
The FDA is reviewing new applications for innovative sleep-promoting medications currently, including suvorexant and tasimelteon. Pre …